- Home
- RGS vs BLRX Comparison
RGS vs BLRX Comparison
Compare RGS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGS
- BLRX
- Stock Information
- Founded
- RGS 1922
- BLRX 2003
- Country
- RGS United States
- BLRX Israel
- Employees
- RGS N/A
- BLRX N/A
- Industry
- RGS Other Consumer Services
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- RGS Consumer Discretionary
- BLRX Health Care
- Exchange
- RGS Nasdaq
- BLRX Nasdaq
- Market Cap
- RGS 63.6M
- BLRX 54.1M
- IPO Year
- RGS 1991
- BLRX 2011
- Fundamental
- Price
- RGS $27.29
- BLRX $0.46
- Analyst Decision
- RGS
- BLRX Strong Buy
- Analyst Count
- RGS 0
- BLRX 2
- Target Price
- RGS N/A
- BLRX $11.50
- AVG Volume (30 Days)
- RGS 68.7K
- BLRX 202.4K
- Earning Date
- RGS 10-30-2024
- BLRX 11-18-2024
- Dividend Yield
- RGS N/A
- BLRX N/A
- EPS Growth
- RGS N/A
- BLRX N/A
- EPS
- RGS 38.34
- BLRX N/A
- Revenue
- RGS $202,982,000.00
- BLRX $17,048,000.00
- Revenue This Year
- RGS N/A
- BLRX N/A
- Revenue Next Year
- RGS N/A
- BLRX N/A
- P/E Ratio
- RGS $0.70
- BLRX N/A
- Revenue Growth
- RGS N/A
- BLRX N/A
- 52 Week Low
- RGS $3.87
- BLRX $0.44
- 52 Week High
- RGS $35.50
- BLRX $1.93
- Technical
- Relative Strength Index (RSI)
- RGS 58.21
- BLRX 23.64
- Support Level
- RGS $25.12
- BLRX $0.50
- Resistance Level
- RGS $28.20
- BLRX $0.56
- Average True Range (ATR)
- RGS 2.05
- BLRX 0.05
- MACD
- RGS 0.26
- BLRX -0.01
- Stochastic Oscillator
- RGS 69.20
- BLRX 10.60
About RGS Regis Corporation
Regis Corp owns, franchises, and operates beauty salons throughout North America and the United Kingdom. The company's locations provide salon products and services to the mass market, including haircutting, styling, and hair coloring. The vast majority of Regis' salons are in strip malls, shopping centers, and Wal-Mart stores in North America and serve price-conscious customers. The company derives the majority of its revenue from these locations. The sale of products also contributes a relatively significant percentage of total sales. Regis also operates a smaller portfolio of premium salons across North America and the U.K. The company's majority brands include SmartStyle, Cost Cutters, and Supercuts.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.